Glaxo, Theravance report Relovair safety data – BusinessWeek

Glaxo, Theravance report Relovair safety data
BusinessWeek
GlaxoSmithKline PLC and Theravance Inc. said Wednesday their lung disease and asthma drug Relovair met its goals in a mid-stage safety study.
GSK and Theravance announce combination ICS/LABA Phase II results in the MarketWatch (press release)
GlaxoSmithKline Reports Positive Results For Phase II Trial Of Relovair In RTT News
Theravance Announces Results From Phase II Study For Developmental Combination Stock Markets Review

all 31 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *